These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 12380158)

  • 1. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 2. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 3. New uses for tenofovir: more questions about d4T.
    Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tenofovir (Viread)].
    Sidahora; 2002; (1):20-1. PubMed ID: 12772661
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir--long term results from first-line therapy.
    TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
    [No Abstract]   [Full Text] [Related]  

  • 6. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
    Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
    [No Abstract]   [Full Text] [Related]  

  • 7. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS
    AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 9. The potential place of tenofovir in antiretroviral treatment regimens.
    Gazzard BG
    Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir: FDA hearing on important new antiretroviral.
    James JS
    AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411
    [No Abstract]   [Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate.
    Gallant JE; Deresinski S
    Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising results for tenofovir.
    AIDS Patient Care STDS; 2000 Jul; 14(7):396. PubMed ID: 10935058
    [No Abstract]   [Full Text] [Related]  

  • 13. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
    [No Abstract]   [Full Text] [Related]  

  • 14. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
    Eagan L
    Posit Living; 2001; 10(5):21. PubMed ID: 11693102
    [No Abstract]   [Full Text] [Related]  

  • 16. [First nucleotide analog on the market. New drug for the pretreated patient].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
    [No Abstract]   [Full Text] [Related]  

  • 17. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of tenofovir.
    AIDS Patient Care STDS; 2002 Jan; 16(1):52. PubMed ID: 11892609
    [No Abstract]   [Full Text] [Related]  

  • 19. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 20. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
    Shere-Wolfe KD; Verley JR
    Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.